No-pharmacotherapy (n = 477) | Anticraving agent (n = 177) | Antidepressants (n = 104) | Statistical value | p | |
---|---|---|---|---|---|
Sex (male %) | 450 (94.5) | 175 (98.9) | 92 (91.1) | 9.20a | 0.010 |
Age | 40.40 ± 10.27 | 37.45 ± 8.04 | 39.58 ± 10.86 | 5.73b | 0.003** |
Age of onset | 30.74 ± 8.92 | 27.87 ± 6.19 | 29.00 ± 8.56 | 8.10b | <0.001** |
With partner (or married) | 307 (63.1) | 113 (64.8) | 53 (51) | 6.52a | 0.038 |
BDI | 10.82 ± 10.66 | 15.00 ± 10.23 | 20.67 ± 11.81 | 6.94b | 0.002** |
BAI | 16.75 ± 9.68 | 20.09 ± 9.24 | 26.60 ± 10.00 | 9.72b | <0.001** |
GSAS | 12.88 ± 9.59 | 20.07 ± 11.83 | 16.88 ± 10.77 | 3.01b | 0.056 |
Group CBT | 68 (14.3) | 39 (22) | 14 (13.6) | 6.23a | 0.044 |
Participation in GA | 106 (25.4) | 54 (34.4) | 26 (27.4) | 4.59a | 0.101 |
Follow-up duration (months) | 5.53 ± 12.37 | 10.37 ± 14.61 | 17.56 ± 26.99 | 27.19 | <0.001** |